Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 5, pp 1686–1693 | Cite as

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis

  • Joseph H. Helm
  • John T. Miura
  • Jason A. Glenn
  • Rebecca K. Marcus
  • Gregory Larrieux
  • Thejus T. Jayakrishnan
  • Amy E. Donahue
  • T. Clark Gamblin
  • Kiran K. Turaga
  • Fabian M. JohnstonEmail author
Regional Cancer Therapies

Abstract

Background

Due to the increased adoption of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients with malignant peritoneal mesothelioma (MPM) have seen improved outcomes. We aimed to evaluate and synthesize the recent published literature.

Methods

The review was conducted according to the recommendation of the Meta-Analysis of Observational Studies in Epidemiology group with prespecified inclusion and exclusion criteria. The DEALE method was used to combine mortality rates, and imputation techniques were used to calculate standard errors. Meta-regression techniques were used to synthesize data. Publication bias was assessed using funnel plots.

Results

Of 6,528 citations collected, 20 articles reporting on 1,047 patients were included in the analysis. The median age was 51 years (interquartile range 49–55), with 59 % (54–67) female. The median peritoneal carcinomatosis index score was 19 (16–23). Complete cytoreduction (CC0, 1) was performed in 67 % (46–93 %) of patients. Pooled estimates of survival yielded a 1-, 3- and 5-year survival of 84, 59, and 42 %, respectively. Patients receiving early postoperative intraperitoneal chemotherapy [EPIC] (44 %) and those receiving cisplatin intraperitoneal chemotherapy alone (48 %) or in combination (44 %) had an improved 5-year survival.

Conclusions

While CRS + HIPEC has led to an improved survival for patients with MPM compared to historic data, heterogeneity of studies precludes generalizable inferences. EPIC chemotherapy and cisplatin chemoperfusion may infer survival benefit.

Keywords

Asbestos Preoperative Chemotherapy Pemetrexed Cytoreductive Surgery Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

DISCLOSURES

No relevant financial disclosures.

References

  1. 1.
    Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Med Gen Med. 2007; 9:32.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007; 18:827–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007; 18:985–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009; 99:109–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005; 7:40–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008; 26:3567–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma: results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009; 64:211–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003; 21:682–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2013; 21(4):1159–65.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007; 31:784–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003; 12:605–21, xi.Google Scholar
  12. 12.
    Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221:29–42.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II: use in medical decision-making. Am J Med. 1982; 73:889–97.CrossRefPubMedGoogle Scholar
  15. 15.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.CrossRefGoogle Scholar
  16. 16.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27:6237–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013; 20:1093–100.CrossRefPubMedGoogle Scholar
  18. 18.
    Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013; 20:555–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007; 14:2790–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol. 2010; 36:1047–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006; 13:405–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001; 67:999–1003.PubMedGoogle Scholar
  23. 23.
    Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am. 1997; 3:174–9.PubMedGoogle Scholar
  24. 24.
    Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000; 87:1587–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992; 118:547–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21:4560–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009; 35:980–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Yonemura Y, Ishibashi H, Canbay E, et al. Treatment results of diffuse malignant peritoneal mesothelioma. Gan To Kagaku Ryoho. 2012; 39:2416–9.PubMedGoogle Scholar
  29. 29.
    Tudor EC, Chua TC, Liauw W, Morris DL. Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma. Am Surg. 2010; 76:400–5.PubMedGoogle Scholar
  30. 30.
    Deraco M, De Simone M, Rossi CR, et al. An Italian multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res. 2003; 22:41–5.PubMedGoogle Scholar
  31. 31.
    Macuks R, Ozdemir H, Dursun P, Ozen OI, Haberal N, Ayhan A. Malignant intraperitoneal mesothelioma-Baskent University experience. J Turk Ger Gynecol Assoc. 2011; 12:104–9.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010; 17:2720–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Chua TC, Yan TD, Deraco M, et al. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98:60-4.CrossRefPubMedGoogle Scholar
  34. 34.
    Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011; 103:822–31.CrossRefPubMedGoogle Scholar
  35. 35.
    Strasberg SM, Hall BL. Postoperative morbidity index: a quantitative measure of severity of postoperative complications. J Am Coll Surg. 2011; 213:616–26.CrossRefPubMedGoogle Scholar
  36. 36.
    Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma: an update on treatment. Cancer Treat Rev. 2012; 38:605–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011; 117:1855–63.CrossRefPubMedGoogle Scholar
  38. 38.
    Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006; 13:229–37.CrossRefPubMedGoogle Scholar
  39. 39.
    Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013; 178:645–51.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Hartz A, Bentler S, Charlton M, et al. Assessing observational studies of medical treatments. Emerg Themes Epidemiol. 2005; 2:8.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Joseph H. Helm
    • 1
  • John T. Miura
    • 1
  • Jason A. Glenn
    • 1
  • Rebecca K. Marcus
    • 1
  • Gregory Larrieux
    • 1
  • Thejus T. Jayakrishnan
    • 1
  • Amy E. Donahue
    • 1
  • T. Clark Gamblin
    • 1
  • Kiran K. Turaga
    • 1
  • Fabian M. Johnston
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Department of SurgeryMedical College of WisconsinMilwaukeeUSA

Personalised recommendations